TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Blog > TGA Eases Timeline for Devices to Comply with Patient Information Requirements

TGA Eases Timeline for Devices to Comply with Patient Information Requirements

Author: Jenny Lin / Senior Manager, Medical Devices / IVD, Australia

In response to challenges sponsors have faced in preparing detailed patient information leaflets (PILs) and patient implant cards (PICs) in time for a 1 December 2021 deadline, the Therapeutics Goods Administration (TGA) has released an update that gives companies some leeway in meeting these requirements.

Initially, all implantable devices (other than those exempted as per Clause 13A.1(b), Schedule 1, part 2 of the Therapeutic Goods (Medical Devices) Regulations 2002) which are included in the Australian Register of Therapeutic Goods (“ARTG) were required to have Patient Information Leaflets (PILs) and Patient Implant Cards (PICs) from 1 December 2021.

 

The TGA released updated guidance on 14 October 2021 which will allow industry to utilise the consent to supply form in the event of any delay in complying with the new PIL/PIC requirements. This change brings the TGA closer in line with similar European requirements, which are expected to be implemented in 2024.

 

What to do if you won’t meet the timeline

 

To ensure continuous supply of a device which does not comply with the PICs/PILs requirements after 1 December 2021, sponsors will need to submit a consent to import, supply, or export a medical device to the TGA, using the TGA guidance. An online consent form is also available on the TGA website. The required information related to non-compliance to the Essential Principles in a consent application includes:

 

  • Selection of specific Essential Principles for which consent is requested (e.g., Clause 13A.2 to 13A.4)
  • Description of the non-compliance with the Essential Principle(s)
  • Requested duration of the consent to supply non-compliant devices, including a reason why those dates have been selected
  • Strategy to mitigate the non-conformance for all ARTG entries/applications. This is an implementation plan that includes information such as the proposed risk mitigation strategy, action plan and when mitigating activities will commence. The TGA has provided examples in the guidance about what is expected of the implementation plan. An interim non-compliant patient card or leaflet should also be uploaded as part of the implementation plan.

 

What you need to be aware of

  • This interim measure is only applicable to existing ARTGs and applications that are made before 1 December 2018. Any new applications or devices that entered the Register on or after 1 December 2018 are not eligible for the consent to supply.
  • While each application may include multiple ARTG entries, if some of the ARTG entries/Applications for Inclusion have different implementation plan(s), interim PICs/PILs or proposed consent durations, a separate consent for supply application will be required.
  • If the device is non-compliant with the Essential Principles, sponsors must ensure they use the correct form. The TGA has provided different forms depending on which Essential Principle the device does not comply with.
  • The processing fees for each entry will be reduced to a flat fee of AU$30 from previous fee schedule comprising AU$500 for the first application, and AU$100 for each subsequent ARTG entry. A refund request for fee difference can be made to the TGA for sponsors who have lodged consent applications on or after 1 January 2021.
  • Electronic PICs and/or PILs rather than hard copies will be considered compliant if they contain all required information and are made available in a way that is readily accessible by the patient concerned. In such case, consent to supply will not be required.

 

More positive change on the horizon

Currently a number of implantables are excluded from the requirement to provide patient information materials, as listed in Schedule 1, part 2 of the Therapeutic Goods (Medical Devices) Regulations 2002. TGA will allow more “similar items” to be added to the excluded list, which may include pedicle and laminar screws. This will be clarified by the TGA in their upcoming guidance.

 

If you have any questions about or need assistance with patient implant cards and/or patient information leaflets in either Australia or Europe, be sure to reach out to PharmaLex team for a no-obligation discussion.

Related posts
Is quality documentation an asset or a burden in regulatory affairs?
Is quality documentation an asset or a burden in regulatory affairs?
6th April 2022
Navigating the impact of the IVDR on marketed products
Navigating the impact of the IVDR on marketed products
24th March 2022
Minimizing risk during the transport of medicinal products
Minimizing risk during the transport of medicinal products
21st March 2022
Next Steps for EUDAMED implementation within MDR
Next Steps for EUDAMED implementation within MDR
7th March 2022
How Advanced Therapeutic Mergers & Acquisitions Impact Negotiations and Integration
How Advanced Therapeutic Mergers & Acquisitions Impact Negotiations and Integration
26th February 2022
Planning for Post-Emergency Use Authorization (EUA) for Medical Devices and IVDs
Planning for Post-Emergency Use Authorization (EUA) for Medical Devices and IVDs
24th February 2022
Recent Blogs
  • Is quality documentation an asset or a burden in regulatory affairs?
    6th April 2022
  • Navigating the impact of the IVDR on marketed products
    24th March 2022
  • Minimizing risk during the transport of medicinal products
    21st March 2022
  • Next Steps for EUDAMED implementation within MDR
    7th March 2022
  • How Advanced Therapeutic Mergers & Acquisitions Impact Negotiations and Integration
    26th February 2022
  • Planning for Post-Emergency Use Authorization (EUA) for Medical Devices and IVDs
    24th February 2022
Recent News
  • Addressing Limitations of Sterility Testing
    9th May 2022
  • Are virtual audits sustainable post-pandemic?
    6th May 2022
  • Orphan Drug Designation: Securing the Significant Benefits
    28th March 2022
  • PharmaLex expands pricing & reimbursement and health economics platform with EBMA Consulting merger
    9th March 2022
  • PharmaLex extends reach to Japan, East Asia and Southeast Asia with Ascent Development Services merger
    8th February 2022
  • Virtual Audits: To be, or not to be, that is the question
    26th January 2022
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
12 May

Patrick Nieuwenhuizen talks to BioPharm International about the Limitations of Sterility Testing and understanding the challenges and solutions of Aseptic Processing.

Read more: https://lnkd.in/d8cq4V6u

#sterilitytesting #asepticprocessing #pharma

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • We couldn’t have asked for a more professional, personable, knowledgeable group of Quality Experts!

    Top 10 Pharma Company, China
    Drug Safety Director
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for